FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

07 Dec 16

Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics (read more...)

- RUTHERFORD, N.J., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling (read more...)
05 Dec 16

Cancer Genetics, Inc. Listed by Merck as a National Reference Laboratory for KEYTRUDA® (pembrolizumab) Companion Diagnostic Testing (read more...)

- Reinforces CGI’s Position as a Leader in Immuno-Oncology & Companion Diagnostics For PD-L1 Testing & Monitoring Company Expects (read more...)

Events

Clinicians
Patients